Bayer/Onyx Stick To Advanced Cancer Setting With Stivarga’s GIST Indication
This article was originally published in The Pink Sheet Daily
New indication for third-line gastrointestinal stromal tumors, an area of high unmet need, builds on candidate’s initial approval in advanced colon cancer.
You may also be interested in...
Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival
Bayer built upon approvals in the U.S., Europe and Japan to launch Stivarga for the first time in Southeast Asia. Well-established cancer treatment centers in Singapore and Malaysia attract patients in the region as well as far afield from the Middle East.
Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.